Celularity, Inc.

How big is Celularity, Inc.?

As of Jun 18, Celularity, Inc. has a market capitalization of 41.67 million, with net sales of 54.22 million and a net profit of -57.89 million over the last four quarters. Shareholder's funds are 8.84 million, and total assets are 314.09 million.

As of Jun 18, Celularity, Inc. has a market capitalization of 41.67 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 54.22 million, while the sum of net profit for the same period is -57.89 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 8.84 million, and total assets amount to 314.09 million.

What does Celularity, Inc. do?

Celularity, Inc. is a blank check company focused on business combinations in the miscellaneous industry, with a market cap of $41.67 million. As of December 2024, it reported net sales of $18 million and a net loss of $13 million.

Overview:<BR>Celularity, Inc. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination, operating in the miscellaneous industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 18 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -13 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 41.67 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 4.70 <BR>Return on Equity: -612.01% <BR>Price to Book: 4.72<BR><BR>Contact Details:<BR>Address: 1325 Avenue of the Americas Fl 25, NEW YORK NY: 10019-6026 <BR>Tel: 1 212 6163700 <BR>Fax: 1 302 6365454

Should I buy, sell or hold Celularity, Inc.?

Is Celularity, Inc. overvalued or undervalued?

As of August 14, 2023, Celularity, Inc. is considered risky due to its overvaluation indicated by a Price to Book Value of 5.64 and an EV to Sales ratio of 1.69, alongside significant operational losses and poor stock performance, contrasting sharply with its peers.

As of 14 August 2023, the valuation grade for Celularity, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 5.64 and an EV to Sales ratio of 1.69, which suggest a premium valuation despite significant operational losses reflected in its negative P/E and ROE of -612.01%. <BR><BR>In comparison to its peers, Celularity's valuation ratios are concerning; for instance, PaySign, Inc. has a P/E of 42.86, while FONAR Corp. shows a fair valuation with a P/E of 8.99. The stark contrast in these ratios highlights Celularity's relative overvaluation in a challenging industry. Additionally, the company's recent stock performance has been poor, with a 1-month return of -47.23% compared to the S&P 500's 2.33%, reinforcing the notion that the stock is struggling significantly.

Is Celularity, Inc. technically bullish or bearish?

As of September 2, 2025, Celularity, Inc. shows a mildly bullish trend with mixed signals from MACD and bearish Bollinger Bands, while underperforming the S&P 500 significantly over the past three years.

As of 2 September 2025, the technical trend for Celularity, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, suggesting some short-term strength. However, the Bollinger Bands are bearish on both weekly and monthly time frames, which is a negative indicator. The KST and OBV are both mildly bullish on a monthly basis, providing some support to the overall stance. <BR><BR>In terms of performance, Celularity has underperformed the S&P 500 across multiple periods, with a significant decline of 89.67% over the past three years compared to a 70.41% gain in the S&P 500. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish signals in the Bollinger Bands and mixed MACD readings.